

Reference:	FOI.20259.26
Subject:	Multiple Myeloma
Date of Request:	21 April 2026

Requested:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
 - Belantamab Mafodotin [Blenrep]
 - Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone
 - Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone
 - Bortezomib [Velcade] ± Dexamethasone
 - Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)
 - Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
 - Carfilzomib [Kyprolis] + Dexamethasone
 - Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)
 - Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
 - Daratumumab [Darzalex] monotherapy
 - Elranatamab
 - Idecabtagene vicleucef [Abecma]
 - Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
 - Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)
 - Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)
 - Lenalidomide [Revlimid] + Dexamethasone
 - Lenalidomide [Revlimid] monotherapy
 - Panobinostat + Bortezomib + Dexamethasone
 - Pomalidomide [Imnovid] + Dexamethasone
 - Selinexor + Bortezomib [Velcade] + Dexamethasone
 - Selinexor + Dexamethasone
 - Talquetamab
 - Teclistamab [Tecvayli]
 - Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]

3. In the last 6 months, how many patients have been initiated* on the following regimens?
 - Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone
 - Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone
 - Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
 - Carfilzomib [Kyprolis] + Dexamethasone
 - Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)

- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
- Lenalidomide [Revlimid] monotherapy
- Lenalidomide [Revlimid] + Dexamethasone
- Selinexor + Bortezomib [Velcade] + Dexamethasone
- Selinexor + Dexamethasone
- Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]

*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation.

4. In the last 6 months, how many patients have received the following second-line treatment?
- Lenalidomide [Revlimid] + Dexamethasone

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with some of the requested information as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding the following details under Section 40(2) of the FoIA:

- The figures in the tables for questions 2 and 3 have been replaced with an asterisk (*) due to the low number of cases (less than 5)
- All the information requested for question 4 due to the low number of cases (less than 5)

It is not within the expectation of these individuals that their personal data would be released into the public domain. This information is classed as personal data of a third party. Therefore, it is being withheld in accordance with the exemption set out in section 40(2) of the FoIA, by virtue of section 40(3)(a) of the FoIA, which permits a public authority to withhold personal data other than the requestor's where the disclosure would breach Data Protection principles.

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB has treated one hundred and eighty-six (186) patients diagnosed with Multiple Myeloma, during the period 1 November 2025 to 30 April 2026.
2. The UHB provides within the table below, the number of patients diagnosed with Multiple Myeloma that were treated with each of the named treatments, as recorded on the ChemoCare system, during the period 1 November 2025 to 30 April 2026.

Treatments	Number
Belantamab Mafodotin [Blenrep]	*
Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	*

Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	0
Bortezomib [Velcade] ± Dexamethasone	5
Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)	11
Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	*
Carfilzomib [Kyprolis] + Dexamethasone	0
Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	*
Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	*
Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	18
Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	27
Daratumumab [Darzalex] monotherapy	23
Elranatamab	*
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	*
Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)	9
Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)	5
Lenalidomide [Revlimid] + Dexamethasone	32
Lenalidomide [Revlimid] monotherapy	33
Panobinostat + Bortezomib + Dexamethasone	0
Pomalidomide [Imnovid] + Dexamethasone	5
Selinexor + Bortezomib [Velcade] + Dexamethasone	*
Selinexor + Dexamethasone	*
Talquetamab	0
Teclistamab [Tecvayli]	0
Any other Systemic Anti-Cancer tTherapy (SACT) for Multiple Myeloma only - Cyclophosphamide	*
Total	186

3. The UHB provides within the table below, the number of patients initiated on the named treatments, as recorded on the ChemoCare system, during the period 1 November 2025 to 30 April 2026.

Treatments	Number
Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	*
Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	0
Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
Carfilzomib [Kyprolis] + Dexamethasone	0
Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	*
Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	*
Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	10
Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	7
Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	*
Lenalidomide [Revlimid] monotherapy	*
Lenalidomide [Revlimid] + Dexamethasone	6
Selinexor + Bortezomib [Velcade] + Dexamethasone	0
Selinexor + Dexamethasone	*
Any other SACT for Multiple Myeloma only – Bortezomib + Dex,	8

Isatuximab, Pomalidomide & dexamethasone and Elranatamab	
Total	46

4. An exemption under Section 40 of the FoIA has been applied.